By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Can-Fite BioPharma Ltd. 

Reinhold Cohn House
P.O.Box: 4060
Tel Aviv      Israel
Phone: 03-7109330 Fax: 03-5606405


Drug Discovery

Company News
Can-Fite BioPharma (CFBI)’s Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting 7/17/2017 6:09:50 AM
Can-Fite BioPharma (CFBI) Concludes Successful Clinical Investigator Meeting For Its Acrobat Phase III Trial Of Piclidenoson In The Treatment Of Rheumatoid Arthritis 6/8/2017 6:25:53 AM
Can-Fite BioPharma (CFBI) Establishes Clinical Advisory Board For NAFLD/NASH 6/5/2017 10:26:30 AM
New Preclinical Data On Can-Fite BioPharma (CFBI)'s Namodenoson To Be Presented At 1st International Conference On Fatty Liver In Seville, Spain On June 2, 2017 6/1/2017 8:05:50 AM
Can-Fite BioPharma (CFBI) Reports First Quarter 2017 Financial Results & Provides Clinical Update 5/30/2017 8:32:23 AM
Can-Fite BioPharma (CFBI) Files Clinical Trial Application In Canada For Piclidenoson Ahead Of Upcoming Acrobat Rheumatoid Arthritis Phase III Study 5/16/2017 7:24:33 AM
Can-Fite BioPharma (CFBI)'s Liver Protective Drug Namodenoson Enters Phase II Trial For Treatment Of NAFLD/NASH 5/3/2017 7:32:04 AM
Can-Fite BioPharma (CFBI)'s Phase III ACRobat Trial In Rheumatoid Arthritis Approved By Institutional Review Board 4/25/2017 6:27:02 AM
Can-Fite BioPharma (CFBI) Reports 2016 Financial Results & Provides Clinical Update 3/31/2017 9:08:55 AM
New Preclinical Data Show Can-Fite BioPharma (CFBI)'s Namodenoson (CF102) Prevents Progression Of Liver Fibrosis 2/28/2017 6:41:17 AM